

EFFECT OF EARLY TREATMENT WITH FLUVOXAMINE ON RISK OF EMERGENCY CARE AND HOSPITALIZATION AMONG PATIENTS WITH COVID-19: THE TOGETHER RANDOMIZED PLATFORM CLINICAL TRIAL

Authors: Gilmar Reis, MD^{1,2}; Eduardo Augusto dos Santos Moreira Silva, MD^{1,2}; Daniela Carla Medeiros Silva, MD^{1,2}; Professor Lehana Thabane, PhD³; Aline Cruz Milagres, RN^{4,5}; Thiago Santiago Ferreira, MD¹; Castilho Vitor Quirino dos Santos^{1,2}; Adhemar Dias de Figueiredo Neto, MD⁶; Eduardo Diniz Callegari, MD⁷; Leonardo Cançado Monteiro Savassi, MD²; Vitoria Helena de Souza Campos,^{1,2} Maria Izabel Campos Simplicio, BScPharm¹; Luciene Barra Ribeiro, RN¹; Rosemary Oliveira¹; Ofir Harari, PhD⁴; Jamie I Forrest, MPH⁴; Hinda Ruton, MSc⁴; Sheila Sprague, PhD³; Paula McKay, MSc³; Alla V Glushchenko, MD,³ PhD, Craig R. Rayner, PharmD, FRCP *Edin*^{10,11}; Professor Eric J. Lenze, MD;¹² Angela M. Reiersen, MD¹²; Professor Gordon H. Guyatt, MD³; Professor Edward J. Mills, PhD, FRCP³; for the TOGETHER Investigators*

**TOGETHER Investigators are listed in the supplementary materials*

Affiliations:

1. Research Division, Cardresearch - Cardiologia Assistencial e de Pesquisa, Brazil
2. Department of Medicine, Pontifícia Universidade Católica de Minas Gerais, Brazil
3. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
4. Cytel Inc, Vancouver, British Columbia, Canada
5. Department of Public Health, Montes Claros State University, Brazil
6. Public Health Fellowship Program, Governador Valadares Public Health Authority, Brazil
7. Public Health, Mental and Family Medicine Department, Ouro Preto Federal University, Brazil
8. Public Health Care Division, City of Ibirité, Brazil
9. Drug Research and Development Center, Federal University of Minas Gerais, Belo Horizonte, Brazil
10. Certara Inc. Princeton, New Jersey, USA
11. Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
12. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA

1 **Corresponding Authors: Gilmar Reis MD, PhD**
2 Director - Research Division
3 CARDRESEARCH – Cardiologia Assistencial e de
4 Pesquisa
5 Associate Professor of Medicine
6 Pontificia Universidade Católica de Minas Gerais
7 Address: Rua Domingos Vieira 300, Sala 606 – Santa Efigenia
8 Belo Horizonte – Minas Gerais
9 Brazil – ZIP: 30.150-242
10 Email: greis@cardresearch.org
11
12 **Edward Mills PhD, FRCP**
13 Professor
14 Health Research Methods, Evidence & Impact
15 McMaster University
16 Hamilton, Ontario, Canada
17 Email: millsej@mcmaster.ca
18 Phone: 778 317 8530

19 ABSTRACT

20 **Background**

21 Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the
22 TOGETHER randomized platform clinical trial for acutely symptomatic patients with COVID-19,
23 we assessed the efficacy of fluvoxamine vs. placebo in preventing either extended emergency
24 room observation or hospitalization due to COVID-19. Herein, we report the preliminary findings.

25 **Methods**

26 This placebo-controlled, randomized, adaptive, platform trial conducted among symptomatic
27 Brazilian adults confirmed positive for SARS-CoV-2 included eligible patients with a known risk
28 factor for progression to severe disease. Patients were randomly assigned to either fluvoxamine
29 (100 mg twice daily for 10 days) or placebo. The primary endpoint was a composite outcome of
30 emergency room observation for >6 hours or hospitalization from COVID-19 up to 28 days post
31 randomization. Secondary outcomes included viral clearance at day 7, time to hospitalization,
32 mortality, and adverse drug reactions. We used a Bayesian analytic framework to determine effects
33 along with probability of success of intervention compared to placebo. The trial is registered at
34 clinicaltrials.gov (NCT04727424) and is ongoing.

35 **Results**

36 The study team screened 9020 potential participants for this trial. The trial was initiated on June
37 2, 2020, with the current protocol reporting randomization from January 15, 2021 to August 6th
38 2021, when the trial arms were stopped for superiority. A total of 3238 patients were allocated to
39 fluvoxamine (n=739), placebo (n=733) and other treatments (n=1766). Herein, we report the
40 effectiveness of fluvoxamine vs. a concurrent placebo control. The average age of participants was

41 50 years (range 18-102 years); 57% were female. The proportion of patients observed in an
42 emergency room for >6 hours or admitted to hospital due to COVID-19 was lower for the
43 fluvoxamine group compared to placebo (77/739 vs 108/733; Relative Risk [RR]: 0.71; 95%
44 Bayesian Credible Interval [95% BCI]: 0.54 - 0.93), with a probability of superiority of 99.4%
45 surpassing the prespecified superiority threshold of 97.6% (risk difference 4.3%). Of the composite
46 primary outcome events, 88% were hospitalizations. We found no significant relative effects
47 between the fluvoxamine and placebo groups on viral clearance at day 7 (Odds ratio [OR]: 0.75;
48 95% Confidence Intervals [95% CI]: 0.53 - 1.07), mortality (OR: 0.70; 95% CI: 0.36 - 1.30), time
49 to death (Hazard ratio [HR]: 0.79; 95% CI: 0.58 - 1.08), days hospitalized (Mean Difference (MD)
50 1.22 days; 95% CI: 0.98 - 1.53), number of days ventilated (MD 1.10; 95% CI: 0.70 - 1.73) or
51 other secondary outcomes. Data capturing all 28 days of follow-up will be reported after August
52 26th, 2021.

53 **Conclusions**

54 Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with
55 early diagnosed COVID-19, reduced the need for extended emergency room observation or
56 hospitalization.

57 **Funding** The trial was supported by FastGrants and The Rainwater Foundation.

58

59 BACKGROUND

60 Although safe and effective vaccines for COVID-19 have been developed and distributed, there
61 remain, particularly in low resource settings, major challenges regarding their production,
62 allocation, and affordability.¹ Identifying inexpensive, widely available and effective therapies
63 against COVID-19 is, therefore, of great importance. In particular, repurposing existing medicines
64 that are widely available and with well understood safety profiles, has particular appeal.²

65 Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) and a Sigma-1 receptor
66 (S1R) agonist.³ There are several potential mechanisms for fluvoxamine in treatment of COVID-
67 19 illness, including anti-inflammatory and possible antiviral effects.⁴ A small placebo-controlled
68 randomized trial has raised the possibility that fluvoxamine may reduce the risk of clinical
69 deterioration in outpatients with COVID-19, suggesting the need for larger randomized, placebo-
70 controlled studies.^{5,6}

71 To evaluate the efficacy of fluvoxamine to prevent progression of COVID-19 and
72 hospitalization among outpatients with laboratory-documented SARS-CoV-2, we conducted a
73 randomized, placebo-controlled adaptive platform trial in Minas Gerais, Brazil. This flexible
74 platform trial design allows for additional agents to be added and tested with standardized
75 operating procedures outlined in a single overarching master protocol.^{7,8} Among eight different
76 interventions evaluated in this platform trial, we report here on the clinical evaluation of
77 fluvoxamine using a concurrent placebo control group.

78 METHODS

79 ***Study design and oversight***

80 The TOGETHER Trial is a randomized adaptive platform trial to investigate the efficacy of
81 repurposed treatments for COVID-19 disease among high-risk adult outpatients.⁹ The trial was
82 designed and conducted in partnership with local public health authorities from eleven
83 participating cities in Brazil to simultaneously test potential treatments for early disease using a
84 master protocol. A master protocol defines prospective decision criteria for discontinuing
85 interventions for futility, stopping due to superiority against placebo, or adding new interventions.
86 Interventions evaluated in the TOGETHER trial, thus far, include, hydroxychloroquine (protocol
87 1), lopinavir/ritonavir (protocol 1),¹⁰ metformin, ivermectin, fluvoxamine, doxazosin and
88 pegylated interferon lambda versus matching placebos (protocol 2).

89 The trial began on June 2, 2020 and enrollment into the fluvoxamine arm began on January
90 15th 2021. The trial, which complied with the International Conference of Harmonization – Good
91 Clinical Practices, as well as local regulatory requirements, was approved for research ethics by
92 local and national ethics boards in Brazil (CONEP CAAE: 41174620.0.1001.5120, approval letter
93 5.501.284) and the Hamilton Integrated Research Ethics Board (HiREB, approval letter 13390) in
94 Canada. The full protocol, statistical analysis plan, and additional details are appended in the web-
95 appendix. The adaptive designs CONSORT extension (ACE) statement guided this trial report.^{16,17}
96 The steering committee made all protocol-related decisions and sponsors had no role in trial
97 conduct, data analysis or decision to submit manuscript for publication. An independent Data
98 Safety Monitoring Committee (DSMC) provided trial oversight.

99

100 **Setting**

101 The appended web-appendix lists the cities and investigators of the eleven clinical sites in Brazil
102 that participated in the trial. Local investigators, in partnership with local public health authorities,
103 recruited participants at community health facilities (emergency settings, flu-symptom referral
104 centers, primary care community centers). We used several community outreach strategies
105 including physical and social media as per local public health authorities, in order to create
106 awareness of the trial.

107 **Participant Screening**

108 Upon presentation to one of the trial outpatient care clinics, local investigators screened potential
109 participants to identify those who met the eligibility criteria.

110 The key inclusion criteria were: 1) patients over the age of 18, 2) presenting to an outpatient
111 care setting with an acute clinical condition consistent with COVID-19 and symptoms beginning
112 within 7 days of the screening date, 3) positive rapid test for SARS-CoV-2 antigen performed at
113 the time of screening or patient with positive SARS-CoV-2 diagnostic test within 7 days of
114 symptom onset, 4) at least one additional criterion for high-risk: diabetes mellitus; systemic
115 arterial hypertension requiring at least one oral medication for treatment; known cardiovascular
116 diseases (heart failure, congenital heart disease, valve disease, coronary artery disease,
117 cardiomyopathies being treated, clinically manifested heart disease and with clinical repercussion);
118 symptomatic lung disease and / or being treated (emphysema, fibrosing diseases); symptomatic
119 asthma patients requiring chronic use of agents to control symptoms; smoking; obesity, defined as
120 BMI > 30 kg / m² (weight and height information provided by the patient); transplant patients;
121 patient with stage IV chronic kidney disease or on dialysis; immunosuppressed patients / using
122 corticosteroid therapy (equivalent to at least 10 mg of prednisone per day) and / or

123 immunosuppressive therapy; patients with a history of cancer in the last 0.5 years or undergoing
124 current cancer treatment, or age ≥ 50 years; and unvaccinated status.

125 Patients who met any of the following criteria were excluded from the trial: 1) Diagnostic
126 examination for SARS-CoV2 negative associated with acute flu-like symptoms (patient with
127 negative test taken early and becoming positive a few days later were eligible, if he/she was <7
128 days after the onset of flu-like symptoms); 2) Acute respiratory condition compatible with COVID-
129 19 treated in the primary care and previously requiring hospitalization; 3) Acute respiratory
130 condition due to other causes; 4) Received vaccination for SARS-CoV2; 5) Dyspnea secondary to
131 other acute and chronic respiratory causes or infections (e.g., decompensated COPD, acute
132 bronchitis, pneumonia, primary pulmonary arterial hypertension); 6) Current use of selective
133 serotonin reuptake inhibitors; uncontrolled psychiatric disorders; or suicidal ideation; 7) Inability
134 or unwillingness to follow research guidelines and procedures. A full list of exclusion criteria are
135 provided in the trial protocol.

136 If a patient met the above eligibility criteria, study personnel obtained written informed
137 consent. After obtaining informed consent a rapid antigen test for COVID-19 (Panbio®, Abbott
138 laboratories) and a pregnancy test for women of childbearing age were performed. If the COVID-
139 19 test was negative or if the pregnancy test was positive, the participant was not included in the
140 trial. After informed consent, study personnel collected the following data prior to randomization:
141 demographics, medical history concomitant medications, co-morbidities, exposure to Index Case
142 information, WHO clinical worsening scale, and the PROMIS Global Health Scale.

143 ***Randomization and Trial Interventions***

144 Participants were randomized using a centralized core randomization process handled by an
145 independent unblinded pharmacist who was not aware of any protocol-related procedures and

146 contracted specifically for this process. Sites requested randomization by text message to the
147 pharmacist at the coordinating center. This maintained concealment of allocation. Patients were
148 randomly assigned using a block randomization procedure for each participating site, stratified by
149 age (< 50 years / ≥ 50 years). The trial team, site staff and patients were blinded to treatment
150 allocation. The active drugs and the placebo pills were packaged in identically shaped bottles and
151 labeled with alphabet letters corresponding to the active arm or placebo arm. Only the third-party
152 pharmacist responsible for releasing the randomization was aware of which letter was associated
153 with which drug and/or placebo. As this is a multi-arm trial and all active interventions have a
154 matching inert placebo, the matching placebo represents the proportion of the control group for
155 the number of arms in the trial at any given time.

156 ***Data Collection and Participant Follow-Up***

157 Our primary outcome is a composite that includes emergency room visits due to the clinical
158 worsening of COVID-19 (defined as participant remaining under observation for > 6 hours) or
159 hospitalization due to the progression of COVID-19 (worsening of clinical status) and/or suspected
160 COVID-19 complications within 28 days of randomization. Key secondary outcomes include: 1)
161 viral clearance, 2) time to clinical improvement, 3) number of days with respiratory symptoms, 4)
162 time to hospitalization for any cause or due to COVID-19 progression, 5) all-cause mortality and
163 time to death from any causes, 7) WHO clinical worsening scale score, 8) days in hospital and on
164 ventilator and 9) adverse events, adverse reactions to the study medications and the proportion of
165 participants who are non-adherent with the study drugs. All secondary outcomes are assessed up
166 to 28 days following randomization.

167 Study personnel collected, via in person, telephone contact and social media applications
168 using video-teleconferencing, outcome data on days 1, 2, 3, 4, 5, 7, 10, 14, and 28. We collected

169 outcome data irrespective of whether participants took study medication. In case of adverse events,
170 unscheduled visits (during the treatment period) outside of clinical care could occur at any time.

171 Considering the transmissible characteristic of SARS-CoV-2 and the isolation
172 recommendations of positive individuals, we collected limited vital sign data. Cardiac safety was
173 assessed using a 6-lead ECG (Kardiamobile, Mountain View, CA) at the baseline visit. The digital
174 recordings were de-identified and transferred to a central facility (Cardresearch, Belo Horizonte,
175 Brazil) for reading. Oxygen status was assessed using a pulse oximeter for non-invasive arterial
176 oxygen saturation (SpO₂) and pulse (Jumper Medical Equipment, Shenzhen, China), and
177 temperature using a standard digital oral thermometer administered by research personnel. Mid-
178 turbinate nasal swab kits and sterile recipient storage were provided for collection of
179 nasopharyngeal swab or sputum/saliva. They were performed by the first quarter of participants
180 enrolled in the trial at days 3 and 7. PCR of viral clearance was assessed to determine if active
181 drugs demonstrate any anti-viral effects.

182 All serious and non-serious adverse events were reported to study personnel as per local
183 regulatory requirements. Reportable adverse events included serious adverse events, adverse
184 events resulting in study medication discontinuation, and adverse events assessed as possibly
185 related to study medication.

186 ***Trial interventions***

187 All participants received usual standard care for COVID-19 provided by healthcare professionals
188 workers at public health facilities. Patients were randomized to fluvoxamine (Luvox ®, Abbott) at
189 a dose of 100 mg twice a day for 10 days or corresponding placebo starting right after
190 randomization (day 1). Research personnel provided participants a welcome video with
191 information on trial, study drug, adverse events and follow-up procedures. Clinicians providing

192 usual care in public health facilities typically focus on the management of symptoms and with
193 antipyretics, and recommend antibiotics only if they suspect bacterial pneumonia.

194 **Statistical Analyses**

195 The Adaptive Design Protocol and the Master Statistical Analysis Plan provide details of sample
196 size calculation and statistical analysis (appended). This trial is adaptive and applies sample size
197 re-estimation approaches. To plan for each arm, we assumed a minimum clinical utility of 37.5%
198 (relative risk reduction) to achieve 80% power with 0.05 two-sided Type 1 error for a pairwise
199 comparison against the placebo (talc) assuming a control event rate (CER) of 15%. This resulted
200 in an initial plan to recruit 681 participants per arm. The statistical team conducted planned interim
201 analyses. Stopping thresholds for futility were established if the posterior probability of superiority
202 was less than 40% at interim analysis. An arm can be stopped for superiority if the posterior
203 probability of superiority meets the threshold of 97.6%

204 Baseline characteristics are reported as count (percent) or median and interquartile range (IQR) for
205 continuous variables. We applied a Bayesian framework for our primary outcome analysis and a
206 frequentist approach for all sensitivity analyses and secondary outcomes. Posterior efficacy of
207 fluvoxamine for the primary outcome is calculated using the beta-binomial model for event rates,
208 assuming informed priors based on the observational data for both placebo and fluvoxamine, for
209 both Intention-to-Treat (ITT), modified ITT (defined as receiving the study drug for at least 24
210 hours before an event) and Per-Protocol (PP) analyses (defined as taking >80% of possible doses).
211 Modified ITT was defined as receiving treatment for at least 24 hours before a primary outcome.
212 We accounted for any temporal changes in events rates by using only the concurrent randomised

213 population. We assessed subgroup effects according to the preplanned statistical analysis plan. We
214 calculated the number needed to treat.

215 Secondary outcomes were assessed using a pre-specified frequentist approach. For viral
216 clearance we fitted a longitudinal, mixed-effect logistic regression model with a treatment and time
217 interaction term for binary patient outcomes (Covid-19 positive/negative) reported on day 3 and 7
218 from randomization, with subject random effect. We assessed time-to-event outcomes using Cox
219 proportional hazard models and binary outcomes using logistic regression. Per protocol analyses
220 were considered sensitivity analyses to assess the robustness of the results. All analyses were
221 performed using R version 4.0.3. Full details of the Statistical Analysis Plan (SAP) are appended.

222 **Data and Safety Monitoring Committee**

223 A Data and Safety Monitoring Committee provided independent oversight for this trial. We
224 planned a 4th interim analysis of the fluvoxamine arm with data collected up to August 2nd, 2021.

225 **Role of the funding source**

226 The funders had no role in the study design, data collection, analysis, interpretation or writing, or
227 decision to submit for publication. The executive committee take responsibility for the integrity of
228 the data and the accuracy of the data analysis. The trial executive committee oversaw all aspects
229 of trial conduct, completeness, data accuracy and adherence of trial conduct to the protocol and
230 the committee vouch for the accuracy and completeness of the data and for fidelity to the protocol.

231

232 **RESULTS**

233 We screened 9020 potential participants for inclusion in this trial to date. The trial enrolled its first
234 participant on June 2, 2020 and enrolment into the fluvoxamine arm began on January 20, 2021.

235 By August 6, 2021, 1,472 recruited participants were randomized to fluvoxamine (n= 739) or the
236 concurrent placebo (n=733), and 1,766 were randomized to other treatment arms (Figure 1). The
237 median age was 50 years (range 18-102) and 846 (57.5%) were women (Table 1). Most
238 participants self-identified as mixed-race 1,403 (95.3%), 11 (0.7%) as white, 10 (0.7%) as black
239 or African American, the rest self-identified as unknown 48 (3.3%). As the trial is ongoing, herein
240 we provide descriptive summaries of only those randomized to fluvoxamine and its concurrent
241 control. With respect to covariates of age, BMI, and co-morbidities, the groups were generally
242 well balanced (Table 1). The mean number of days with symptoms prior to randomization was 4
243 days (Standard Deviation 1.76). All patients were identified at the end of the study for inclusion
244 in the analysis.

245 **Primary Outcomes**

246 The Data Safety Monitoring Committee met four times since the protocol initiation and last met
247 on August 5, 2021, recommending that the TOGETHER Trial stop randomizing patients to the
248 fluvoxamine arm, as this comparison had met the pre-specified superiority criterion for the primary
249 endpoint (prespecified superiority threshold 97.6%). Based on the Bayesian beta-binomial model,
250 there was evidence of a benefit of fluvoxamine reducing hospitalization or observation in an
251 emergency room for greater than six hours due to COVID-19 (Relative Risk [RR]: 0.71; 95%
252 Bayesian Credible Interval [BCI]: 0.54 - 0.93) in the Intention-to-Treat (ITT) population (figure
253 2A) and (RR: 0.68; 95% BCI: 0.50 - 0.91) in a modified ITT population (figure 2B). The
254 probability that the event rate was lower in the fluvoxamine group compared to placebo was 99.4%
255 for the ITT population, and 99.6% for the modified ITT population (Figure 2A/B). These posterior
256 efficacy numbers were higher than the pre-specified 97.6% threshold set for the fourth interim
257 analysis. In the fluvoxamine group 77 (10.4%) participants experienced a primary outcome event

258 compared to 108 (14.7%) in the placebo group (Table 2). Most events (88%) were hospitalizations.
259 The number needed to treat is 24. Per protocol analysis demonstrated a larger treatment effect
260 (0.34, 95% BCI, 0.20-0.54).

261 ***Secondary Outcomes***

262 Table 3 presents findings from secondary outcome analyses. There were no significant differences
263 between fluvoxamine and placebo for viral clearance at Day 7 (p=0.18) and eFigure3 in web-
264 appendix, hospitalizations due to COVID (p=0.17), all-cause hospitalizations (p=0.12), time to
265 hospitalization (p=0.14, number of days in hospital (p=0.07), mortality (p=0.26), time to death
266 (p=0.26), number of days on mechanical ventilation (p=0.67), time to recovery (p=0.86) or the
267 PROMIS Global Health Scale (p=0.44). With respect to adverse events, there were significantly
268 greater number of Grade 1 (mild) treatment emergent adverse events (TEAE) among patients in
269 the fluvoxamine arm (p<0.01). However, no differences between fluvoxamine and placebo were
270 observed for TEAEs of Grades 2, 3, 4, or 5.

271 ***Sub-group Analyses***

272 In the prespecified subgroup analysis, we found no evidence of moderation of treatment effect for
273 fluvoxamine compared to placebo, for sub-groups of age, sex, days since symptom onset, or co-
274 morbidities (Figure 3 and web-appendix eTable 1).

275

276 **DISCUSSION**

277 This is the first large randomized controlled trial to test the efficacy of fluvoxamine for acute
278 treatment of COVID-19. We found a clinically important absolute risk reduction of 4.3%, and
279 29% relative risk reduction, on the primary outcome of retention in an emergency setting for
280 COVID-19 disease observation or hospitalization, consequent on the administration of

281 fluvoxamine for 10 days. This study is only the 2nd study to demonstrate an important treatment
282 benefit for a repurposed drug in the early treatment population.¹¹ Our findings represent the latest
283 interim analysis of the trial resulting in the DSMC recommending stopping the active fluvoxamine
284 arm. The final analysis from the trial, wherein all patients have contributed 28 days of follow-up
285 data, will be made available 28 days after the last randomized patient has completed this period
286 (August 25, 2021). Given fluvoxamine's safety, tolerability, ease of use, low cost, and widespread
287 availability, these findings may have influence on national and international guidelines on the
288 clinical management of COVID-19.

289

290 **Comparison with prior evidence**

291 Our results are consistent with an earlier smaller trial conducted in the United States (led by EJJ
292 and AMR).⁶ That study used a higher dose of fluvoxamine (100mg tid for 15 days) and included
293 a lower risk group for the primary outcome but found no clinical deterioration among 80 patients
294 receiving fluvoxamine vs. 6 of 72 patients receiving placebo. A large observational study from
295 France involved a different population, 7230 hospitalized COVID-19 patients, and reported a
296 reduction in use of intubation or death with use of SSRIs.⁵

297 The underlying mechanism of fluvoxamine for COVID-19 disease remains uncertain. Although
298 hypotheses include several potential mechanisms,⁴ the main reason for the initial study of
299 fluvoxamine as a treatment of COVID-19 was its anti-inflammatory action through activation of
300 the σ -1 receptor (S1R).¹² S1R is an endoplasmic reticulum (ER) chaperone membrane protein
301 involved in many cellular functions,¹³ including regulation of ER stress response/unfolded protein
302 response and regulation of cytokine production in response to inflammatory triggers.¹⁴ In the
303 presence of fluvoxamine, S1R may prevent the ER stress sensor Inositol-Requiring Enzyme 1 α

304 (IRE1) from splicing and activating the mRNA of X-Box Protein 1 (XBP1), a key regulator of
305 cytokine production including IL-6, IL-8, IL-1 β and IL-12. In a 2019 study by Rosen and
306 colleagues, fluvoxamine showed benefit in preclinical models of inflammation and sepsis through
307 this mechanism.¹⁴

308 Another mechanism may be fluvoxamine's anti-platelet activity.¹⁵ SSRIs can prevent loading of
309 serotonin into platelets and inhibit platelet activation, that may reduce the risk of thrombosis, and
310 these antiplatelet effects can be cardioprotective. In vitro and animal studies are needed to help
311 clarify the most likely mechanism(s). Biomarker studies included as part of future RCTs may also
312 help to clarify mechanisms.

313

314 **Strengths and limitations**

315 Since the start of the COVID-19 pandemic, there have been more than 2800 RCTs registered on
316 clinicaltrials.gov. However, less than 300 have been reported and the vast majority of clinical trials
317 have been small and underpowered, with sample sizes less than 100. In many cases, these trials
318 have been unsuccessful at recruiting as the local epidemics occur in waves and sustainable
319 infrastructure to maintain staff or local interest for recruitment is lacking. The trials that provide
320 the clearest medical understanding tend to be the larger platform trials, such as SOLIDARITY,¹⁶
321 RECOVERY,¹⁷ PRINCIPLE,¹¹ and REMAP-CAP.¹⁸ As a result, we actively collaborate with other
322 investigators running trials with overlapping interventions so that they can be aware of our study
323 decisions and determine whether they should influence their respective trials.

324 Major strengths include the rapid recruitment and enrolment of high-risk patients for the
325 development of severe COVID-19. Our recruitment strategy involves the engagement with the
326 local public health system, thus allowing recruitment that frequently exceeds twenty patients per

327 day. We enrolled only participants with diagnosed COVID-19 and less than 7 days of symptom
328 onset using a commercially available COVID-19 AG rapid test (Panbio ®). The concordance of
329 COVID-19 positive tests with RT-PCR was evaluated on the group of participants with PCR
330 evaluations and found a concordance rate of > 99% on both tests collected at baseline.

331 Our understanding of the epidemiology of COVID-19 as well as its disease progression and
332 outcomes have evolved since beginning this platform trial in June 2020. Early studies assessed the
333 effects of interventions of viral load and clearance, while later studies also evaluate more clinical
334 outcomes. We made adjustments to the trial according to prespecified rules and in communication
335 with the appropriate ethics review committees that allowed us to respond to the epidemic waves
336 while maintaining high rates of recruitment. Unlike many outpatient clinical trials, our study
337 involves direct patient contact through the use of medical students, nurses and physicians who do
338 at-home visits as well as follow-up via telecommunications. Given the rapid recruitment of patients
339 in combination with the high event rate of emergency room visits and hospitalizations, we were
340 able to evaluate the effects of interventions when portions of the planned population had been
341 recruited. The period of time between first recruitment of a patient on fluvoxamine and the data
342 cut for our trial was 197 days. Our trial assessed a primary outcome as a binary event having
343 occurred by 28 days post-randomization.

344 One of the major limitations of our fluvoxamine trial is primarily related to the challenges of
345 conducting a trial in a disease that is not well characterized. Currently, there is no standard of care
346 that exists for early treatment of COVID-19 and various advocacy groups promote different
347 interventions, including some of those evaluated in this and our previous trials. Furthermore, there
348 is little understanding of who is at greatest risk of disease progression from this disease as some
349 patients with numerous risk factors do recover quickly while some others with less established risk

350 factors may not. Our population had a higher rate of hospitalization events than observed in most
351 clinical trials, thus permitting inferences on treatment effects in this higher-risk population.

352

353 **Implications**

354 Our trial has found that fluvoxamine, an inexpensive existing drug, reduces the need for advanced
355 disease care in this high-risk population. A ten-day course of fluvoxamine costs approximately \$4
356 even in well-resourced settings.¹⁹ Our study compares favorably and exceeds the treatment effects
357 of more expensive treatments including monoclonal antibodies for outpatient treatment.^{20,21} The
358 absolute number of serious adverse events associated with fluvoxamine was lower than our
359 placebo group and this might reflect the modulatory effect of fluvoxamine on systemic
360 inflammation in these participants. Lower respiratory tract infections were reported less frequently
361 in patients in the fluvoxamine group than those in the placebo group. This is concordant with the
362 reduction of hospital admissions in patients with confirmed COVID-19 treated with fluvoxamine,
363 and the numerically lower number of patients requiring mechanical ventilation.

364

365 Fluvoxamine is widely available but is not on the WHO Essential Medicines List,²² whereas a
366 closely related SSRI fluoxetine is on the list. It is now of critical importance to determine whether
367 a class-effect exists and whether these drugs can be used interchangeably for COVID-19. The
368 recent important findings that inhaled budesonide increased time to recovery among a similar
369 population as our trial and had a trend towards decreased hospitalizations suggests this as an
370 alternative or additional intervention for outpatient care that should be evaluated. The PRINCIPLE
371 trial evaluated time to recovery using self-reported recovery up to 28 days after randomization to
372 budesonide.¹¹ Our trial differed as we evaluated improvement in the WHO categorization of

373 disease disability up to days 14 and then 28 (web-appendix eFigure 2). Finally, our study was
374 among unvaccinated patients. Further evidence of treatment benefits are needed to determine the
375 effect of fluvoxamine among vaccinated populations.

376 Use of interventions, including fluvoxamine, to prevent progression of illness and hospitalization
377 is critically dependent on identifying higher risk individuals. Unselected populations will have a
378 lower risk. What absolute reduction in risk of clinical deterioration would motivate patients to
379 choose treatment (probably the >4% we observed, but perhaps not much lower) remains uncertain.
380 These considerations raise the importance of the development of a validated prediction rule for
381 deterioration in patients in the early stages of COVID-19 infection.

382 **Conclusion**

383 Administration of fluvoxamine reduced the rate of prolonged observation in an emergency care
384 setting or hospitalization due to COVID-19 in people with a high risk of serious disease.

385

386

387

388

389

390

391

392

393

394

395

396 **ACKNOWLEDGEMENTS**

397 The trial was supported by FastGrants and the Rainwater Foundation. GR and EJM had full access
398 to all the data in the study and take responsibility for the integrity of the data and the accuracy of
399 the data analysis. Our research network consists of partnerships between academics and clinicians
400 at McMaster University in Ontario, Canada, and Pontificia Universidade Catolica de Minas Gerais,
401 Claros State University, and University of Ouro Preto in Minas Gerais, Brazil. Other partners
402 include Cytel, Platform Life Sciences, MMS Holdings, WHO Therapeutic Guidelines Committee,
403 and the Society for Clinical Trials. Trial documents are found on the Open Science Framework
404 (<https://doi.org/10.17605/OSF.IO/EG37X>). Trial data are shared with the International COVID-
405 19 Data Alliance (ICODA). The work has been presented and reviewed by the WHO Platform
406 Trials Group.

407 **Data Safety and Monitoring Committee (DSMC) Members:** William Cameron, University of
408 Ottawa (Canada), James Orbinski, York University (Canada), Sonal Singh, University of
409 Massachusetts (USA), Kristian Thorlund, McMaster University (Canada), Jonas Haggstrom of
410 Cytel Inc. (Sweden).

411

412

413

414 **REFERENCES**

415

- 416 1. Torres I, Artaza O, Profeta B, Alonso C, Kang J. COVID-19 vaccination: returning to
417 WHO's Health For All. *Lancet Glob Health* 2020; **8**(11): e1355-e6.
- 418 2. Rayner CR, Dron L, Park JJH, et al. Accelerating Clinical Evaluation of Repurposed
419 Combination Therapies for COVID-19. *Am J Trop Med Hyg* 2020; **103**(4): 1364-6.
- 420 3. Omi T, Tanimukai H, Kanayama D, et al. Fluvoxamine alleviates ER stress via induction
421 of Sigma-1 receptor. *Cell Death Dis* 2014; **5**(7): e1332.
- 422 4. Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: A Review of Its
423 Mechanism of Action and Its Role in COVID-19. *Front Pharmacol*.2021;12:652688. doi:
424 10.3389/fphar.2021.652688. eCollection 2021
- 425 5. Hoertel N, Sánchez-Rico M, Vernet R, et al. Association between antidepressant use and
426 reduced risk of intubation or death in hospitalized patients with COVID-19: results from an
427 observational study. *Mol Psychiatry* 2021.
- 428 6. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical
429 Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. *Jama*
430 2020; **324**(22): 2292-300.
- 431 7. Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and
432 platform trials: a landscape analysis of master protocols. *Trials* 2019; **20**(1): 572.
- 433 8. Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple
434 Diseases, or Both. *N Engl J Med* 2017; **377**(1): 62-70.
- 435 9. Reis G, Silva EAdSM, Silva DCM, et al. A multi-center, adaptive, randomized, platform
436 trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease
437 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. *Gates*
438 *Open Research* 2021; **5**(117): 117.
- 439 10. Reis G, Moreira Silva E, Medeiros Silva DC, et al. Effect of Early Treatment With
440 Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With
441 COVID-19: The TOGETHER Randomized Clinical Trial. *JAMA Netw Open* 2021; **4**(4): e216468.
- 442 11. Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at
443 high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled,
444 open-label, adaptive platform trial. *The Lancet*.
- 445 12. Nicol GE, Karp JF, Reiersen AM, Zorumski CF, Lenze EJ. "What Were You Before the
446 War?" Repurposing Psychiatry During the COVID-19 Pandemic. *J Clin Psychiatry* 2020; **81**(3).
- 447 13. Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor
448 chaperones and their potentiation of neurite outgrowth in PC12 cells. *Eur J Pharmacol* 2014; **727**:
449 167-73.


- 450 14. Rosen DA, Seki SM, Fernández-Castañeda A, et al. Modulation of the sigma-1 receptor-
451 IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. *Sci Transl Med* 2019;
452 **11**(478).
- 453 15. Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet
454 activation: can they prevent acute myocardial infarction? *Am J Cardiovasc Drugs* 2003; **3**(3): 149-
455 62.
- 456 16. Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral Drugs for Covid-19 -
457 Interim WHO Solidarity Trial Results. *N Engl J Med* 2021; **384**(6): 497-511.
- 458 17. Horby PW, Pessoa-Amorim G, Peto L, et al. Tocilizumab in patients admitted to hospital
459 with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label,
460 platform trial. *medRxiv* 2021: 2021.02.11.21249258.
- 461 18. Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ
462 Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid
463 Domain Randomized Clinical Trial. *Jama* 2020; **324**(13): 1317-29.
- 464 19. Wang J, Levi J, Ellis L, Hill A. Minimum manufacturing costs, national prices and
465 estimated global availability of new repurposed therapies for COVID-19. *medRxiv* 2021.
- 466 20. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in
467 Outpatients with Covid-19. *N Engl J Med* 2021; **384**(3): 229-37.
- 468 21. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody
469 Cocktail, in Outpatients with Covid-19. *N Engl J Med* 2021; **384**(3): 238-51.
- 470 22. Organization WH. World Health Organization model list of essential medicines: 21st list
471 2019: World Health Organization, 2019.

472

473

474 TABLES & FIGURES


Figure 1: Participant Flowchart



475
476
477
478
479
480
481
482

483 **Figure 2:** Probability of efficacy and Bayesian relative risk of extended emergency room
484 observation or hospitalization for fluvoxamine vs. placebo (Panel A: ITT population; Panel B:
485 Modified ITT population)

486 A) *Intention-to-treat analysis*



487


488

489

490

491 B) *Modified intention-to-treat analysis*


492



493

494 **Figure 3:** Sub-group analyses of fluvoxamine vs. placebo in the TOGETHER Trial

495



496

497 **Table 1.** Patient characteristics by treatment allocation in the TOGETHER Trial

| | Fluvoxamine (n=739) | Placebo (n=733) | Total (n=1472) |
|-------------------------------------|--------------------------------------|----------------------------------|---------------------------------|
| Sex | | | |
| Female | 408(55.2) | 438(59.8) | 846(57.5) |
| Male | 331(44.8) | 295(40.2) | 626(42.5) |
| Race | | | |
| Mixed Race ⁺ | 708(95.8) | 695(94.8) | 1403(95.3) |
| White | 5(0.7) | 6(0.8) | 11(0.7) |
| Black or African American | 5(0.7) | 5(0.7) | 10(0.7) |
| Unknown | 21(2.8) | 27(3.7) | 48(3.3) |
| Age, years | | | |
| >= 50 years | 325(44.0) | 318(43.4) | 643(43.7) |
| Age Descriptive Statistics | | | |
| Median | 50 | 49 | 50 |
| IQR | 17 | 18 | 18 |
| Body Mass Index (BMI) | | | |
| <30 kg/m ² | 354(47.9) | 360(49.1) | 714(48.5) |
| >=30 kg/m ² | 372(50.3) | 359(49.0) | 731(49.7) |
| Unspecified | 13(1.8) | 14(1.9) | 27(1.8) |
| Time since onset of symptoms | | | |
| 0-3 days | 318(43.0) | 296(40.4) | 614(41.7) |
| 4-7 days | 241(32.6) | 249(34.0) | 490(33.3) |
| Unspecified | 180(24.3) | 188(25.7) | 368(25.0) |
| Risk factors | | | |

| | | | |
|--|-----------|----------|-----------|
| Chronic cardiac disease | 8(1.1) | 8(1.1) | 16(1.1) |
| Hypertension | 106(14.4) | 88(12.0) | 194(13.2) |
| Chronic pulmonary disease | 6(0.8) | 3(0.4) | 9(0.6) |
| Asthma | 11(1.5) | 16(2.2) | 27(1.8) |
| Chronic kidney disease | 2(0.3) | 2(0.3) | 4(0.3) |
| Rheumatologic disorder | 1(0.1) | 0(0.0) | 1(0.1) |
| Chronic neurological disorder | 8(1.1) | 6(0.8) | 14(1.0) |
| Diabetes mellitus: Type 1 | 25(3.4) | 22(3.0) | 47(3.2) |
| Diabetes mellitus: Type 2 | 103(14.0) | 93(12.7) | 196(13.3) |
| Obesity | 2(0.3) | 1(0.1) | 3(0.2) |
| Any other risk factor(s) or co-morbidities | 24(3.3) | 19(2.6) | 43(2.9) |

498 **LEGEND:** *Self-identified as someone with mixed-race ancestry.

499 **Table 2:** Proportion of primary outcome events and relative risk of extended emergency room
500 observation or hospitalization of fluvoxamine vs. placebo

| | Intention-to-treat analysis | | | Modified intention-to-treat analysis | | |
|-------------|-----------------------------|--------------|----------------------------|--------------------------------------|-------------|----------------------------|
| | N | n (%) | Relative risk (95% CrI) | N | n (%) | Relative risk (95% CrI) |
| Fluvoxamine | 739 | 77 (10.4 %) | 0.71 [0.54; 0.93] | 728 | 66(9.1 %) | 0.68 [0.50; 0.91] |
| Placebo | 733 | 108 (14.7 %) | 1.00 (ref) | 722 | 97(13.4 %) | 1.00 (ref) |
| All | 1472 | 185 (12.6%) | -- | 1450 | 163(11.2 %) | -- |

501 **LEGEND:** 95% CrI – Credible intervals

502

503 **Table 3:** Secondary outcomes of fluvoxamine vs placebo in the TOGETHER Trial

| | Fluvoxamine | Placebo | Estimated treatment effect (95% CI) | p-value |
|---|-------------------------|-----------------------|--|----------------|
| Viral clearance (Day 7) | 45/218 (21%) | 57/217 (26%) | 0.73 (0.47, 1.14) * | 0.17 |
| Hospitalized for COVID | 74/739 (10.0%) | 90/733 (12.3%) | 0.79 (0.57, 1.10) * | 0.17 |
| All-cause hospitalization | 74/739 (10.0%) | 92/733 (12.6%) | 0.77 (0.56, 1.07) * | 0.12 |
| Time to hospitalization | 5 days [3 to 7] | 5 days [3 to 7] | 0.79 (0.58, 1.08) † | 0.14 |
| Number of days of hospitalization | 7 days [5 to 12.5] | 6 days [3 to 10.75] | 1.22 (0.98, 1.53) ‡ | 0.07 |
| Emergency room visit for at least 6 hours | 6/739 (0.8%) | 30/733 (4.1%) | 0.19 (0.07, 0.43) * | <0.01 |
| Time to the emergency visit for at least 6 hours | 5.5 days [4.25 to 6.75] | 6 days [3.25 to 8.75] | 0.19 (0.08, 0.47) † | <0.01 |
| Death | 17/739 (2.3%) | 24/733 (3.3%) | 0.70 (0.36 to 1.30) * | 0.26 |
| Time to death | 17 days [9 to 21] | 14 days [8 to 20] | 0.79 (0.58 to 1.08) | 0.26 |
| Number of days on mechanical ventilator | 7 days [3 to 12] | 6.5 days [3 to 12] | 1.10 (0.70 to 1.73) ‡ | 0.67 |
| Adherence | 541/739 (73.2%) | 609/733 (83.1%) | 0.48 (0.36, 0.63) * | <0.01 |
| Grade 1 TEAE | 17/739 (2.3%) | 5/733 (0.7%) | 3.43 (1.35 to 10.47) * | 0.02 |
| Grade 2 TEAE | 62/739 (8.4%) | 74/733 (9.4%) | 0.82 (0.57 to 1.16) * | 0.26 |
| Grade 3 TEAE | 34/739 (4.2%) | 43/733 (4.6%) | 0.77 (0.48 to 1.23) * | 0.28 |
| Grade 4 TEAE | 18/739 (2.3%) | 20/733 (2.2%) | 0.89 (0.46 to 1.70) * | 0.72 |
| Grade 5 TEAE | 18/739 (2.2%) | 25/733 (2.3%) | 0.71(0.38 to 1.30) * | 0.27 |

504 **LEGEND:** TEAE: Treatment Emergent Adverse Event

505 Summary statistics are presented as n/N or median (IQR) unless otherwise stated.

506 * Unadjusted odd ratio

507 † Unadjusted hazard ratio.

508 ‡Exponentiated unadjusted estimates from a log-transformed linear regression.

509